Please assess the completion status of the following clinical trial:

Trial Title: Greek NIS Spiolto ELLACTO

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Therapeutic indication before entering the enrollment face is patients diagnosed with COPD requiring a combination therapy of two long-acting bronchodilators (LAMA + LABA) according to approved SmPC and guidelines, COPD GOLD 2017 groups B to D~* Female and male patients ≥40 years of age~* Treatment with Spiolto ® Respimat® acc. to SmPC and at the discretion of the physician~* Written informed consent prior to participation~Exclusion Criteria:~* Patients with contraindications according to Spiolto® Respimat® SmPC~* Patients who have been treated with a LABA/LAMA combination (free and fixed dose) in the previous 6 weeks or patients already on a combination of LAMA and LABA therapy; either as a fixed combination product or as separate components Note: Patients previously treated with LABA or LAMA (with or without ICS) are eligible to be included in the study~* Patients continuing LABA-ICS treatment should not be additionally treated with Spiolto® Respimat® in order to avoid a double dosing of long-acting beta-agonists~* Patients for whom further follow-up is not possible at the enrolling site during the planned study period of approx. 6 weeks~* Pregnancy and lactation~* Patients currently listed for lung transplantation~* Current participation in any clinical trial or any other non-interventional study of a drug or device

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- COPD patients (Type: None): Chronic obstructive pulmonary disease

Based on this trial design, predict the completion outcome and termination type (if applicable).